Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension.

被引:153
作者
Archer, Stephen L. [1 ]
Michelakis, Evangelos D. [2 ]
机构
[1] Univ Chicago, Dept Med, Cardiol Sect, Chicago, IL 60637 USA
[2] Univ Alberta, Dept Med, Div Cardiol, Edmonton, AB, Canada
基金
加拿大创新基金会; 美国国家卫生研究院; 加拿大健康研究院;
关键词
ORAL SILDENAFIL; INHALED ILOPROST; NITRIC-OXIDE; THERAPY; EXPRESSION; PDE5; PROLIFERATION; DYSFUNCTION; ACTIVATION; BOSENTAN;
D O I
10.1056/NEJMct0904473
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 46-year-old woman presents with progressive exertional dyspnea and recurrent exertional syncope. Her jugular venous pressure is 16 cm of water, and moderate peripheral edema is noted. Auscultation reveals a pronounced pulmonic component of the second heart sound and a grade 2/6 holosystolic murmur of tricuspid regurgitation. Echocardiography shows moderate right ventricular and right atrial enlargement, right ventricular systolic dysfunction, and an estimated right ventricular systolic pressure of 100 mm Hg. Cardiac catheterization reveals a mean right atrial pressure of 13 mm Hg, a pulmonary-artery pressure of 80/40 mm Hg (mean, 58), a mean pulmonary-capillary wedge pressure of 10 mm Hg, and a cardiac output of 5 liters per minute. The results of additional studies to detect causes of secondary pulmonary hypertension or associated conditions are unremarkable, and she receives a diagnosis of idiopathic pulmonary arterial hypertension. Her pulmonary- artery pressure does not decrease in response to inhaled nitric oxide. Therapy with sildenafil is recommended.
引用
收藏
页码:1864 / 1871
页数:8
相关论文
共 42 条
  • [1] Primary pulmonary hypertension - A vascular biology and translational research "work in progress"
    Archer, S
    Rich, S
    [J]. CIRCULATION, 2000, 102 (22) : 2781 - 2791
  • [2] NITRIC-OXIDE AND CGMP CAUSE VASORELAXATION BY ACTIVATION OF A CHARYBDOTOXIN-SENSITIVE K-CHANNEL BY CGMP-DEPENDENT PROTEIN-KINASE
    ARCHER, SL
    HUANG, JMC
    HAMPL, V
    NELSON, DP
    SHULTZ, PJ
    WEIR, EK
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (16) : 7583 - 7587
  • [3] sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension
    Black, SM
    Sanchez, LS
    Mata-Greenwood, E
    Bekker, JM
    Steinhorn, RH
    Fineman, JR
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2001, 281 (05) : L1051 - L1057
  • [4] Endothelial dysfunction in pulmonary hypertension
    Budhiraja, R
    Tuder, RM
    Hassoun, PM
    [J]. CIRCULATION, 2004, 109 (02) : 159 - 165
  • [5] Pulmonary Vascular Disease in the Developing World
    Butrous, Ghazwan
    Ghofrani, Hossein Ardeschir
    Grimminger, Friedrich
    [J]. CIRCULATION, 2008, 118 (17) : 1758 - 1766
  • [6] SURVIVAL IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION - RESULTS FROM A NATIONAL PROSPECTIVE REGISTRY
    DALONZO, GE
    BARST, RJ
    AYRES, SM
    BERGOFSKY, EH
    BRUNDAGE, BH
    DETRE, KM
    FISHMAN, AP
    GOLDRING, RM
    GROVES, BM
    KERNIS, JT
    LEVY, PS
    PIETRA, GG
    REID, LM
    REEVES, JT
    RICH, S
    VREIM, CE
    WILLIAMS, GW
    WU, M
    [J]. ANNALS OF INTERNAL MEDICINE, 1991, 115 (05) : 343 - 349
  • [7] European Medicines Agency, REV PROD INF
  • [8] Galiè N, 2006, NEW ENGL J MED, V354, P1092
  • [9] Sildenafil citrate therapy for pulmonary arterial hypertension
    Galiè, N
    Ghofrani, HA
    Torbicki, A
    Barst, RJ
    Rubin, LJ
    Badesch, D
    Fleming, T
    Parpia, T
    Burgess, G
    Branzi, A
    Grimminger, F
    Kurzyna, M
    Simonneau, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) : 2148 - 2157
  • [10] Tadalafil Therapy for Pulmonary Arterial Hypertension
    Galie, Nazzareno
    Brundage, Bruce H.
    Ghofrani, Hossein A.
    Oudiz, Ronald J.
    Simonneau, Gerald
    Safdar, Zeenat
    Shapiro, Shelley
    White, R. James
    Chan, Melanie
    Beardsworth, Anthony
    Frumkin, Lyn
    Barst, Robyn J.
    [J]. CIRCULATION, 2009, 119 (22) : 2894 - U65